[CDC], 2009a; Department of Health Education and Welfare, 1964). The benefits of this achievement are not spread evenly, however, as people living in poverty, those with lower education, and persons with mental health diagnoses continue to smoke at high rates. As smoking prevalence decreases in the general population but remains high in subgroups, these subgroups bear a disproportionate burden of smoking-related illness and also frame new targets for both smoking cessation intervention and tobacco control.One population with elevated smoking prevalence includes those with substance use disorders. A developed literature indicates that smokers with other addictions smoke more heavily (Hays et al., 1999;J. Hughes, 2002;J. R. Hughes, 1996;Kozlowski, Jelinek, & Pope, 1986;Marks, Hill, Pomerleau, Mudd, & Blow, 1997;Sobell, 2002), are less successful in their attempts to quit smoking (Bobo, Gilchrist, Schilling, Noach, & Schinke, 1987;Drobes, 2002;Joseph, Nichol, & Anderson, 1993;Kozlowski, Skinner, Kent, & Pope, 1989;Sobell, 2002;Zimmerman, Warheit, Ulbrich, & Auth, 1990), and are more likely to die from smoking-related causes than from other substance-related causes (Hser, McCarthy, & Anglin, 1994;Hurt et al., 1996).The National Comorbidity Study (NCS) was a national sample (n = 8,098) of noninstitutionalized U.S. persons aged 15-54 years, designed to estimate national prevalence of mental illness. NCS data reported smoking prevalence of 56.1% among persons with past-month alcohol disorders and 67.9% among those with substance use disorders (Lasser et al., 2000). The National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) is a general population survey (N = 43,093) including noninstitutionalized U.S adults and weighted to be representative of the larger U.S population. NESARC data show that smoking prevalence is 34.5% among those with alcohol disorders and 52.4% among those with substance use disorders (Grant, Hasin, Chou, Stinson, & Dawson, 2004).Smoking prevalence may be even higher among those who seek treatment for their alcohol or other drug addiction. Current literature cites smoking prevalence among addiction treatment clients as ranging between 49% and 98% (Schroeder, AbstractIntroduction: This review explores whether smoking prevalence in addiction treatment samples exceeds that shown in epidemiological data for persons with alcohol or other drug use disorders and whether smoking may have decreased over time in the addiction treatment population as it has done in the general population.Methods: English language papers published between 1987 and 2009 were searched electronically. Forty papers reporting smoking prevalence for addiction treatment samples in the United States were identified, and key predictor variables were abstracted. Random logistic models were used to assess relationships between each individual predictor (year, treatment modality, primary drug treated, government status, and public/ private funding status) and smoking prevalence. Results:The lowest smoking prevalence aggre...
Aims Smoking prevalence is higher among persons enrolled in addiction treatment as compared to the general population, and very high rates of smoking are associated with opiate drug use and receipt of opiate replacement therapy (ORT). We assessed whether these findings are observed internationally. Methods PubMed, PsycINFO and the Alcohol and Alcohol Problems Science Database were searched for papers reporting smoking prevalence among addiction treatment samples, published in English, from 1987 to 2013. Search terms included tobacco use, cessation, and substance use disorders using AND/OR Boolean connectors. For 4,549 papers identified, abstracts were reviewed by multiple raters. 239 abstracts met inclusion criteria and these full papers were reviewed for exclusion. 54 studies, collectively including 37,364 participants, were included. For each paper we extracted country, author, year, sample size and gender, treatment modality, primary drug treated, and smoking prevalence. Results The random-effect pooled estimate of smoking across persons in addiction treatment was 84% (CI 79%, 88%), while the pooled estimate of smoking prevalence across matched population samples was 31% (CI 29%, 33%). The difference in the pooled estimates was 52% (CI 48%, 57%, p < .0001). Smoking rates were higher in programs treating opiate use as compared to alcohol use (OR = 2.52, CI 2.00, 3.17), and higher in ORT compared to outpatient programs (OR = 1.42, CI 1.19, 1.68). Conclusions Smoking rates among people in addiction treatment are more than double those of people with similar demographic characteristics. Smoking rates are also higher in people being treated for opiate dependence compared with people being treated for alcohol use disorder.
The aims of this review were to assess smoking prevalence among drug abuse treatment staff and summarize the range of barriers to provision of nicotine dependence intervention to clients receiving addictions treatment. A systematic literature search was conducted to identify publications reporting on workforce smoking prevalence, attitudes toward smoking, and perceived barriers to providing smoking cessation treatment in drug abuse treatment settings. Twenty papers met study inclusion criteria. Staff smoking prevalence estimates in the literature ranged from 14% to 40%. The most frequently reported barriers to providing nicotine dependence intervention in addiction treatment settings were lack of staff knowledge or training in this area, that smoking cessation concurrent with other drug or alcohol treatment may create a risk to sobriety, and staff are themselves smokers. Staff smoking is not uniformly elevated in the drug abuse treatment workforce. Smoking prevalence may be lower where staff are more educated or professionally trained, and may be higher in community-based drug treatment programs. Barriers to treating nicotine dependence may be addressed through staff training, policy development, and by supporting staff to quit smoking. State departments of alcohol and drug programs, and national and professional organizations, can also support treatment of nicotine dependence in drug abuse treatment settings.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.